Navigation Links
BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
Date:4/9/2008

FREDERICK, Md., April 9, 2008 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will start airing a new commercial for its ActiPatch (TM) technology on Bloomberg Television, April 14, 2008. The company has initiated an advertising contract that calls for the informational commercial to run for the next two weeks, and will reach millions of viewers daily. CEO Andrew Whelan comments, "This is a new initiative for BioElectronics Corporation and we are excited that this commercial will inform consumers, physicians, and distributors about our ActiPatch(TM) products. This national advertisement should help us reach a new level in both product and brand awareness."

The new bio-electronic super-bandage has produced significant rapid healing results in trials and has already received regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

"ActiPatch (TM)" is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery. Trials are ongoing in multiple areas.

The new ActiPatch(TM) retail product line targets five common conditions that affect hundreds of millions of people throughout the world: 1) Back pain, 2) Foot and ankle pain, including ankle sprains and plantar fasciitis, 3) Knee pain, 4) Arm and wrist pain, including carpal tunnel and tennis elbow. BioElectronics has planned an aggressive retail introduction of these products for locations outside of the United States where regulatory clearance has been received. Distribution is expected in Canada, Italy, Netherlands, Australia, Mexico, United Kingdom, the Middle East, and other countries over the next few months.

About BioElectronics

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling.

For more information visit: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
4. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
7. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
8. OmniGuide Begins European Commercialization
9. Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success
10. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
11. Anesiva to Unveil Zingo(TM) Commercialization Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... its research and education building. A topping out ceremony on Friday marked the halfway ... The building, set to open in Fall 2018, will serve as a center for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, ... announced during the 2017 Annual HIMSS Conference & Exhibition in Orlando, ... patients and integrating eye care into mainstream healthcare delivery is powered by ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... with a glitch reveal in just a few clicks of a mouse. Customizable glitch style ... preset. Use these presets to add a uniquely animated logo to any photos or videos. ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... will join forces with Healthwise ® at HIMSS 2017 to ... leader in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... February 20, 2017 According to a new market ... Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), ... MarketsandMarkets, The market is projected to reach USD 52.37 Billion by 2021 ... the forecast period. Continue Reading ... ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
(Date:2/19/2017)... Fla. , Feb. 18, 2017 Nektar ... positive Phase 1 clinical data for Nektar,s lead immuno-oncology ... were presented at ASCO GU 2017.  NKTR-214 is an ... cells and Natural Killer (NK) cell abundance directly in ... these immune cells.  The results were presented by ...
Breaking Medicine Technology: